With Humira facing a patent cliff in the United States in 2023, AbbVie is counting on Skyrizi and Rinvoq to compensate. While Humira rung up sales of $20.7 billion last year, Skyrizi and Rinvoq ...

Share on Pinterest Humira will soon have a citrate-free biosimilar available on the market. Humira (adalimumab) is a popular medication used to treat various inflammatory conditions including ...

AbbVie boosted its EPS expectations to $10.71 and $10.91 per share for the full year, an increase from its previous forecast of $10.61 to $10.81 per share. (AbbVie) With a new chief at the helm and ...

FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

AbbVie already has blockbuster drugs for ulcerative colitis, but that isn’t stopping the pharmaceutical giant from trying to expand its scope in this disease. To that end, the company is acquiring ...

AbbVie, Inc. ABBV announced top-line data from the phase III maintenance study, COMMAND, which evaluated its IL-23 drug Skyrizi (risankizumab) in adult patients with moderately to severely active ...

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...